FMP
We provide one of the most accurate financial data available on the market. You can get historical prices, fundamental data, insider transactions, and much more that goes back 30 years in history.
Get started70,000+ Stocks with tons of data
Welcome to our comprehensive suite of tools designed to streamline your financial data integration process.
Access user-friendly RESTful API documentation suitable for all skill levels.
Detailed endpoint documentation.
Clear request/response examples.
Streamlined navigation.
Ensures clarity/reliability.
Explore endpoints hassle-free with our code-free API Playground.
Interactive data tools.
User-friendly interface.
Download data in CSV/Excel.
Ideal for hands-on exploration.
Real-time Prices, Historical Data and Indicators.
Financial Statements, Key Metrics, Stock Financial Scores and more.
Stock News, Press Releases and Experts Articles.
Company Outlook, Market Capitalization, Company Core Information.
Quality data is key to making accurate, informed decisions. All our data is licensed and sourced from curated third-party data partners, such as the U.S. Securities and Exchange Commission (SEC), Board of Governors of the Federal Reserve System.
See DocumentationWe provide one of the most accurate data available on the market. We spent years designing endpoints and made them informative, well-documented, and easy to use.
Our API has over 100 endpoints and we are still growing and adding new endpoints every week. Every endpoint is available in JSON format and most of them also in CSV format.
We also provide on demand custom endpoint available for our enterprise plan.
See documentationStay Updated and Harness the Power of Our API with the Latest News!
Apr 3, 2025 2:00 AM - Andrew Wynn
Franklin Covey Co. (NYSE: FC) is a key player in the organizational performance improvement sector. The company specializes in providing subscription-based content, training, and tools designed to drive systemic changes in human behavior. FC operates within the Zacks Consulting Services industry, co...
Apr 2, 2025 6:22 PM - Davit Kirakosyan
Bank of America is maintaining a Buy rating and $765 price target on Meta Platforms (NASDAQ:META) as the company reportedly gears up to introduce a new line of premium smart glasses—a potential game-changer for its hardware strategy. The upcoming device, codenamed Hypernova, is expected to launch by...
Apr 2, 2025 6:19 PM - Davit Kirakosyan
Scotts Miracle-Gro (NYSE:SMG) shares rose around 4% intra-day today after Truist Securities upgraded the company from Hold to Buy, maintaining a $70 price target, as the firm sees the stock offering compelling value amid a stabilizing lawn and garden market. Analysts believe that the U.S. lawn and g...
Apr 2, 2025 6:17 PM - Davit Kirakosyan
Clear Street initiated coverage on MicroStrategy (NASDAQ:MSTR) with a Buy rating and a $422 price target, highlighting the company’s distinct approach to leveraged Bitcoin exposure as a key differentiator from traditional crypto investment vehicles like ETFs. Unlike passive instruments, MicroStrateg...
Apr 2, 2025 6:15 PM - Davit Kirakosyan
UBS maintained its Buy rating and $490 price target on Ulta Beauty (NASDAQ:ULTA), citing signs of stabilization in the retailer’s market position and improved conditions across several key areas. Analysts pointed to recent data suggesting that Ulta’s market share has leveled off, indicating a potent...
Apr 2, 2025 6:12 PM - Davit Kirakosyan
ESS Tech (NYSE:GWH) shares dropped more than 6% intra-day today after TD Cowen downgraded the company from Buy to Hold, with analysts slashing the price target from $10 to $3, citing mounting challenges tied to leadership changes, funding concerns, and extended timelines for profitability. While ack...
Apr 2, 2025 5:49 PM - Davit Kirakosyan
UBS downgraded Reinsurance Group of America (NYSE:RGA) from Buy to Neutral, setting a price target of $216. The downgrade reflects growing concerns that short-term upside may be limited, even as the company aggressively pursues long-term growth. While UBS acknowledges that RGA’s management is target...
/